NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NYSE · Biotechnology · USD

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Analysis

Ginkgo Bioworks Holdings, Inc. (DNA) is a Biotechnology stock listed on NYSE and quoted in US Dollar.

Last Updated: October 21, 2026

DNA

$10.01

+$0.15 (+1.52%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare DNA with… →

DNA Key Statistics

As of Oct 21, 2026
Trading
Open
$9.88
Previous Close
$9.86
Day's Range
9.61–10.07
52-Week Range
5.37–18.22
Volume
1.77M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.80
Valuation
Market Cap
$674.08M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
5.09
EPS (ttm)Profit attributable to each share over the last twelve months.
−5.06
Financials (FY)
Revenue (FY)
$170.16M−25.06%
Net Income (FY)
−$312.76M
Profit marginThe share of revenue left as profit after all costs and taxes.
−219.61%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
55.38M
1-Year Return
−23.76%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
2.02M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, DNA closed at $10.01, −23.76% over 1 year.

Ginkgo Bioworks Holdings, Inc. (DNA) has a market capitalization of $674.08M.

In fiscal 2025, DNA reported revenue of $170.16M.

DNA Stock Return by Calendar Year

Ginkgo Bioworks Holdings, Inc. (DNA) return since Apr 2021: what $10,000 became

1 year
$10,000 $7,624
−23.76%
5 years
$10,000 $189
−98.11%
Since Apr 2021
$10,000 $247
−97.53%

If you had invested $10,000 in Ginkgo Bioworks Holdings, Inc. (DNA) at the close on April 19, 2021, the earliest close on record here, it would have been worth $247 at the close on October 21, 2026: −97.53% in total, −48.93% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+20.46%
2025−15.38%
2024−85.47%
2023+0.00%
2022−79.66%
2021 (partial year)−17.89%

As of October 21, 2026.

DNA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$170.16M−$312.76M−183.8%
2024$227.04M−$547.03M−240.9%
2023$251.46M−$892.87M−355.1%
2022$477.71M−$2.10B−440.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$170.16M$123.18M−$303.88M−$312.76M−183.8%
2024$227.04M$182.50M−$487.73M−$547.03M−240.9%
2023$251.46M$197.45M−$768.20M−$892.87M−355.1%
2022$477.71M$273.49M−$2.21B−$2.10B−440.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

DNA Valuation vs Biotechnology Median

Median of 608 stocks
MetricDNABiotechnology medianvs median
P/S ratio5.0913.3062% below
Profit margin−219.61%−38.31%181.3 pts below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Ginkgo Bioworks Holdings, Inc. (DNA) carries a market capitalisation of $674.08M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 485 employees.

The 52-week range on file runs from $5.37 to $18.22. DNA last closed at $10.01 on October 21, 2026. That is +$0.15 (+1.52%) against the previous close. The latest close sits 86.41% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $170.16M. That is −25.06% against the prior fiscal year, when revenue was $227.04M. The same year closed with a net loss of $312.76M. Profit margin runs at −219.61%. That is 181.3 percentage points below the Biotechnology median of −38.31%. Trailing earnings per share are −5.06.

Across the 4 fiscal years on file, revenue moves from $477.71M in 2022 to $170.16M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 5.09. On price-to-sales that is 61.72% below the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The trailing one-year total return is −23.76%. Measured over 5 years, that is −54.76% a year compounded. Beta against the wider market is reported at 1.8. Daily returns over the trailing 5 years annualize to a volatility of 100.32%.

Growth & Income

The record shows no dividend for DNA.

So far in 2026 the total return is +20.46%. Across the complete calendar years on file, 2023 returned 0.00% and 2024 returned −85.47%. Of the 4 complete calendar years on file, 0 finished higher.

Peer Comparison

Ginkgo Bioworks Holdings, Inc. (DNA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Ginkgo Bioworks Holdings, Inc. DNA $674.08M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Ginkgo Bioworks Holdings, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Visit website →